1st 0 3 0 3 O
line 4 8 4 8 O
NSCLC 9 14 9 14 B-cancer
must 15 19 15 19 O
demonstrate 20 31 20 31 O
to 32 34 32 34 O
express 35 42 35 42 O
PD 43 45 43 45 B-treatment
- 45 46 45 46 I-treatment
L1 46 48 46 48 I-treatment

Activating 0 10 49 59 O
EGFR 11 15 60 64 B-clinical_variable
mutation 16 24 65 73 I-clinical_variable
, 24 25 73 74 O
ALK 26 29 75 78 B-clinical_variable
, 29 30 78 79 O
ROS1 31 35 80 84 B-clinical_variable
translocation 36 49 85 98 I-clinical_variable
/ 49 50 98 99 I-clinical_variable
rearrangements 50 64 99 113 I-clinical_variable
are 65 68 114 117 O
not 69 72 118 121 O
permitted 73 82 122 131 O

Availability 0 12 132 144 O
of 13 15 145 147 O
tumor 16 21 148 153 B-cancer
specimen 22 30 154 162 O
taken 31 36 163 168 O
within 37 43 169 175 O
1 44 45 176 177 B-upper_bound
year 46 50 178 182 I-upper_bound
prior 51 56 183 188 I-upper_bound
to 57 59 189 191 O
study 60 65 192 197 O
entry 66 71 198 203 O
, 71 72 203 204 O
with 73 77 205 209 O
no 78 80 210 212 O
intervening 81 92 213 224 O
systemic 93 101 225 233 B-treatment
anti 102 106 234 238 I-treatment
- 106 107 238 239 I-treatment
cancer 107 113 239 245 I-treatment
therapy 114 121 246 253 I-treatment

Combination 0 11 254 265 O
A 12 13 266 267 O
: 13 14 267 268 O
Phase 15 20 269 274 O
1b 21 23 275 277 O
, 23 24 277 278 O
patients 25 33 279 287 O
with 34 38 288 292 O
NSCLC 39 44 293 298 B-cancer
that 45 49 299 303 O
have 50 54 304 308 O
progressed 55 65 309 319 O
on 66 68 320 322 O
standard 69 77 323 331 B-treatment
therapy 78 85 332 339 I-treatment
or 86 88 340 342 O
for 89 92 343 346 O
which 93 98 347 352 O
no 99 101 353 355 O
standard 102 110 356 364 O
therapy 111 118 365 372 O
is 119 121 373 375 O
available 122 131 376 385 O
, 131 132 385 386 O
and 133 136 387 390 O
Phase 137 142 391 396 O
2 143 144 397 398 O
, 144 145 398 399 O
patients 146 154 400 408 O
with 155 159 409 413 O
NSCLC 160 165 414 419 O
, 165 166 419 420 O
melanoma 167 175 421 429 B-cancer
, 175 176 429 430 O
SCCHN 177 182 431 436 B-cancer
, 182 183 436 437 O
TNBC 184 188 438 442 B-cancer
in 189 191 443 445 O
any 192 195 446 449 O
line 196 200 450 454 O
of 201 203 455 457 O
therapy 204 211 458 465 O
, 211 212 465 466 O
SCLC 213 217 467 471 O
, 217 218 471 472 O
1st 219 222 473 476 O
line 223 227 477 481 O
NSCLC 228 233 482 487 O

Combination 0 11 488 499 O
B 12 13 500 501 O
: 13 14 501 502 O
Phase 15 20 503 508 O
1b 21 23 509 511 O
, 23 24 511 512 O
patients 25 33 513 521 O
with 34 38 522 526 O
advanced 39 47 527 535 O
solid 48 53 536 541 B-cancer
tumors 54 60 542 548 I-cancer
( 61 62 549 550 O
NSCLC 62 67 550 555 B-cancer
, 67 68 555 556 O
SCCHN 69 74 557 562 B-cancer
, 74 75 562 563 O
melanoma 76 84 564 572 B-cancer
) 84 85 572 573 O
that 86 90 574 578 O
have 91 95 579 583 O
progressed 96 106 584 594 O
on 107 109 595 597 O
standard 110 118 598 606 B-treatment
therapy 119 126 607 614 I-treatment
or 127 129 615 617 O
for 130 133 618 621 O
which 134 139 622 627 O
no 140 142 628 630 O
standard 143 151 631 639 O
therapy 152 159 640 647 O
is 160 162 648 650 O
available 163 172 651 660 O
, 172 173 660 661 O
and 174 177 662 665 O
Phase 178 183 666 671 O
2 184 185 672 673 O
, 185 186 673 674 O
patients 187 195 675 683 O
with 196 200 684 688 O
NSCLC 201 206 689 694 O
, 206 207 694 695 O
melanoma 208 216 696 704 O
, 216 217 704 705 O
or 218 220 706 708 O
SCCHN 221 226 709 714 O

Histological 0 12 715 727 O
or 13 15 728 730 O
cytological 16 27 731 742 O
diagnosis 28 37 743 752 O
of 38 40 753 755 O
advanced 41 49 756 764 B-cancer
/ 49 50 764 765 I-cancer
metastatic 50 60 765 775 I-cancer
solid 61 66 776 781 I-cancer
tumor 67 72 782 787 I-cancer

Measurable 0 10 788 798 O
disease 11 18 799 806 O
by 19 21 807 809 O
RECIST 22 28 810 816 O
1.1 29 32 817 820 B-lower_bound
with 33 37 821 825 O
at 38 40 826 828 O
least 41 46 829 834 O
1 47 48 835 836 O
measurable 49 59 837 847 O
lesion 60 66 848 854 O
that 67 71 855 859 O
has 72 75 860 863 O
not 76 79 864 867 O
been 80 84 868 872 O
previously 85 95 873 883 O
irradiated 96 106 884 894 B-treatment

